Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11927516 | 0.72 | MAOA (0.36) | MAOAMAOBCYP2C19SETD7CHRM2 | |
| SCHEMBL12712111 | 0.62 | MAOA (0.38) | MAOAMAOBCYP2C19SETD7CHRM2 | |
| SCHEMBL15157450 | 0.62 | MAOA (0.38) | MAOAMAOBCYP2C19CHRM2CHRM1 | |
| SCHEMBL8342687 | 0.61 | MAOA (0.44) | MAOAMAOBCYP2C19SETD7CHRM2 | |
| SCHEMBL26639396 | 0.61 | MAOA (0.33) | MAOAMAOBCYP2C19 | |
| SCHEMBL22450601 | 0.60 | MAOA (0.36) | MAOAMAOBCYP2C19SETD7CHRM2 | |
| SCHEMBL19932911 | 0.60 | MAOA (0.36) | MAOAMAOBCYP2C19 | |
| Bromide SCHEMBL9737718 | 0.60 | MAOA (0.37) | MAOAMAOBCYP2C19SETD7CHRM2 | |
| SCHEMBL17624446 | 0.60 | MAOA (0.42) | MAOAMAOBCYP2C19SETD7CHRM2 | |
| SCHEMBL13149748 | 0.58 | MAOA (0.34) | MAOAMAOBCYP2C19SETD7CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | MAOA 601/4885MAOB 320/4885CYP2C19 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.